Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

[1]  M. Decramer,et al.  The Effect of Tiotropium on COPD GOLD Stage II during the Four-Year UPLIFT Trial. , 2009, ATS 2009.

[2]  Does pharmacotherapy reduce the rate of decline of lung function in COPD? , 2009, American journal of respiratory and critical care medicine.

[3]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[4]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[5]  N. Zhong,et al.  The Efficacy and Safety of Combination Salmeterol (50 μg)/Fluticasone Propionate (500 μg) Inhalation Twice Daily Via Accuhaler in Chinese Patients With COPD , 2007 .

[6]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[7]  R. Pauwels,et al.  The severity of airways obstruction as a determinant of treatment response in COPD , 2006, International journal of chronic obstructive pulmonary disease.

[8]  C. Jenkins,et al.  The TORCH (TOwards a Revolution in COPD Health) survival study protocol , 2004, European Respiratory Journal.

[9]  R. Pauwels,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary Updated 2003 , 2004, COPD.

[10]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[11]  N. Hanania,et al.  The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD , 2003 .

[12]  S. Spencer,et al.  Bronchodilator reversibility testing in chronic obstructive pulmonary disease , 2003, Thorax.

[13]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[14]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[15]  N. Hanania,et al.  The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. , 2003, Chest.

[16]  J. Yates,et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.